menu
    • menu
    [{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Lyrus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lobeglitazone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tamsulosin","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Rabeprazole","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Famotidine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Triple Hair","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Akums Drugs & Pharmaceuticals Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Akums Drugs & Pharmaceuticals Ltd

    Menu

    Akums Drugs & Pharmaceuticals Ltd

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Finasteride,Latanoprost,Minoxidil

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Triple Hair

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Akums Drugs inks licensing pact with Canadian firm Triple Hair Inc

                            Details : Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.

                            Brand Name : Therapy-07

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2024

                            Lead Product(s) : Finasteride,Latanoprost,Minoxidil

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Triple Hair

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Famotidine,Calcium Carbonate,Magnesium Hydroxide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akums Launches Dual Action Heartburn Relief Chewable Tablet

                            Details : Dual action heartburn relief chewable tablet, consisting Famotidine (H2 receptor antagonist), Calcium Carbonate and Magnesium Hydroxide have been approved and launched in indian market.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2024

                            Lead Product(s) : Famotidine,Calcium Carbonate,Magnesium Hydroxide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rabeprazole,Levosulpiride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akums Launches Rabeprazole + Levosulpiride SR Capsules for GERD in India

                            Details : Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase, indicated for treating gastric and duodenal ulcers, as well as GERD.

                            Brand Name : Rabeprazole-Levosulpiride-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2024

                            Lead Product(s) : Rabeprazole,Levosulpiride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamsulosin,Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akums Introduces Tamsulosin + Tadalafil Capsule — to the Indian Market

                            Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 15, 2023

                            Lead Product(s) : Tamsulosin,Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akums Gets DCGI Nod for Triple Combination Diabetes Medication

                            Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2023

                            Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Lyrus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Akums, Lyrus Life Sciences Collaborate for Patented Technologies and Formulations

                            Details : Akums and Lyrus will ensure the launch of patented drugs and more patient-friendly formulations, in the areas of pain, obesity, diabetes, psoriasis, seasonal flu, respiratory insufficiency, immunity and women’s health with a special focus on geriatric ...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Lyrus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lobeglitazone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Akums Receives DCGI Approval for Type 2 Diabetes Drug to Improve Insulin Resistance

                            Details : Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone to improve glycaemic control in adult type 2 diabetes.

                            Brand Name : Lobeglitazone-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 06, 2023

                            Lead Product(s) : Lobeglitazone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Akums Drugs & Pharmaceuticals Ltd

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Biophore India Pharmaceuticals Pvt Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Akums Drugs Enters into a Joint Association with Leiutis and Biophore for First-of-its-kind Therapeutics

                            Details : The partnership aims to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 01, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Biophore India Pharmaceuticals Pvt Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth